John CLIMAX, one of ICON's two co-founders, has served as a Director and Chief Executive Officer of ICON and its subsidiaries since June 1990. In November 2002, he was appointed Executive Chairman. He has over 25 years of experience in the contract research industry in both Europe and the United States.
ICON today is the forth largest global drug development organization which manages clinical trials in all major therapeutic areas, including CNS, cardiology, dermatology, endocrinology, gastroenterology, infectious diseases, oncology, pain management, paediatrics, respiratory, and urology. ICON was listed in the US on NASDAQ in 1998.
Dublin, Ireland, September 27, 2005 - ICON plc (NASDAQ: ICLR), a global contract clinical research organisation, which has approximately 2,800 employees providing services to the pharmaceutical, biotech and medical device industries from 37 locations in 23 countries worldwide, reported the financial results for its fourth quarter ended August 31, 2005.